Navigation Links
Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:11/27/2013

SAN DIEGO, Nov. 27, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the 25th Annual Piper Jaffray Healthcare Conference in New York. The presentation is scheduled for Tuesday, December 3rd  at 11:00 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which the Company is evaluating in the Light Study, a cardiovascular outcomes trial being conducted under a Special Protocol Assessment (SPA) with the FDA. Based on successful results of the Light Study, the Company plans to resubmit the Contrave NDA to the FDA with potential approval by June 2014.The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com. Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Announces Successful Interim Analysis of Contrave Light Study
2. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
3. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
4. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
5. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
6. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
7. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
8. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
9. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
10. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
11. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  Labvantage Lx, a ... its first male sexual enhancement product, EnduramenT. Setting ... proven ethnobotanicals with a patented biomedical breakthrough molecule ... the chemical compound responsible for many biological functions ... Forgoing the use of prescription ...
(Date:2/8/2016)... ISELIN, N.J. , Feb. 8, 2016 ... ), a medical device company focused on ... technologies, today announced today announced that it ... on Wednesday, February 17, 2015 at 9:00 ... and to discuss its corporate strategy, advancements ...
(Date:2/8/2016)... N.Y. , Feb. 8, 2016 In a historic vote ... of plans to construct a medical cannabis cultivation facility and dispensary on ... State of New York as a provider for patients in ... New York as a provider for patients in the state,s ... to 29% (34) to approve the project and pursue designation from the ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... ... A man who has struggled to quit smoking, a man who has struggled with hair ... solutions to his problems – and he did. Now Nabat, a serial entrepreneur featured as ... breakthrough inventions to the world and better people's lives. His own experience with nicotine addiction ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling ... handle, you are not alone. According to the Center for Disease Control and Prevention ... type 2 diabetes and certain types of cancer, some of the leading causes of ...
(Date:2/8/2016)... ... 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the families ... teamed up with Citizens Opposed to Domestic Abuse in support of its efforts to ... those victimized by the fear of violence in their own homes, donations may now ...
(Date:2/8/2016)... ... 2016 , ... Local insurance agency Dennis Fuller & Associates, ... initiated a fundraiser for a two year old little girl named Bella, whose ... support this beautiful child who is facing life’s journey without her loving mother, ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
Breaking Medicine News(10 mins):